T2 Biosystems Shareholders Vote for CRG Debt Conversion into Equity
April 11, 2024 16:05 ET
|
T2 Biosystems, Inc.
LEXINGTON, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced...
T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.
March 28, 2024 09:00 ET
|
T2 Biosystems, Inc.
LEXINGTON, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced...
T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates
March 20, 2024 07:30 ET
|
T2 Biosystems, Inc.
LEXINGTON, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes,...
T2 Biosystems to Host Investor Call on March 20, 2024 to Unveil its T2Lyme Launch Plans and Provide Additional Business Updates
March 19, 2024 09:00 ET
|
T2 Biosystems, Inc.
LEXINGTON, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes,...
T2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance Panel
March 18, 2024 09:00 ET
|
T2 Biosystems, Inc.
LEXINGTON, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes,...
T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement
March 12, 2024 09:00 ET
|
T2 Biosystems, Inc.
LEXINGTON, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced...
T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2023 Financial Results
February 15, 2024 16:06 ET
|
T2 Biosystems, Inc.
LEXINGTON, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes,...
T2 Biosystems Announces Agreement with CRG for the Conversion of $15 Million of CRG Term Loan into Equity
February 15, 2024 16:04 ET
|
T2 Biosystems, Inc.
LEXINGTON, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced...
T2 Biosystems Announces Commercial Expansion Through Distributors in Europe and Asia
February 15, 2024 16:02 ET
|
T2 Biosystems, Inc.
LEXINGTON, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the...
T2 Biosystems Receives FDA 510(k) Clearance for the Expanded T2Bacteria Panel
February 12, 2024 09:00 ET
|
T2 Biosystems, Inc.
LEXINGTON, Mass., Feb. 12, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced...